As per Market Research Future Analysis, the Patient Derived Xenograft Model Market was valued at 0.32 USD Billion in 2024 and is projected to reach 1.1 USD Billion by 2034, growing at a CAGR of 13.30% from 2025 to 2034. The market is driven by increasing cancer-related R&D spending, with significant investments from academia, pharmaceutical firms, and research institutions aimed at improving cancer treatment outcomes. The breast cancer segment led the market in 2022, while the mice model type generated the most revenue. North America dominated the market with a 45.80% share in 2022, primarily due to its robust pharmaceutical sector.
The market is witnessing significant growth due to increased R&D investments and collaboration.
Key players include Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, and Abnova Corp.
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
The market for patient-derived xenograft (PDX) models is growing as a result of rising cancer-related research and development (R&D) expenditures. Stakeholders from academia, pharmaceutical firms, and research institutions are devoting significant financial resources to advancing our understanding of cancer biology and accelerating the development of novel therapies as the burden of cancer keeps rising and the demand for more effective treatments grows. The acceptance and development of the PDX model market are significantly impacted by this increased R&D spending.
Spending on R&D for cancer research has significantly increased in recent years. Governments, private organizations, and biopharmaceutical firms have acknowledged the importance of treating the numerous and intricate problems brought on by different cancer kinds. Significant funding for cancer-related R&D demonstrates a dedication to encouraging innovations that could lead to better patient outcomes. Researchers are looking for more complex and therapeutically applicable techniques to better simulate human cancer biology and response to treatments as a direct result of this infusion of money. The PDX models are useful in this situation.
Immunodeficient mice are implanted with patient tumor tissue in PDX models, which closely mimic the complexity and variety of human malignancies. They offer a setting for evaluating prospective treatments in one that more closely resembles the clinical setting. To build and maintain PDX models, however, significant resources are needed, including as laboratory space, knowledgeable manpower, and specialized tools. These resource needs are directly addressed by the increased R&D money going into the cancer sector, allowing researchers to create and use PDX models more successfully.
The increased R&D expenditures promote industrial and academic cooperation. In order to advance the implementation of PDX models, this collaboration is essential since it makes it possible to share resources, knowledge, and skills. Academic researchers working on PDX-based initiatives can receive financial and technical help from industry partners, which makes it easier to turn scientific discoveries into useful applications. On the other hand, academic institutions can add new perspectives and creative ideas to the PDX model ecosystem as a whole. Thus, driving the Patient derived xenograft model market revenue.
The Patient derived xenograft model market segmentation, based on tumor type, includes lung cancer, pancreatic cancer, prostate cancer, breast cancer and other cancer. The breast cancer segment dominated the market in 2022. The treatment landscape for particular breast cancer subtypes has changed thanks to targeted medicines including HER2-targeted medications and hormone therapy. Researchers can examine combination medications and evaluate the effectiveness of these targeted therapies using PDX models.
The Patient derived xenograft model market segmentation, based on model type, includes mice and rats. The mice category generated the most income in 2022. Mice are widely used as hosts for patient tumor tissues because they are biologically relevant and have a higher genetic similarity to humans than other animals. This biological similarity enhances the ability to translate research findings from PDX models to human clinical trials.
Figure 1: Patient Derived Xenograft Model Market, by model type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
The Patient derived xenograft model market segmentation, based on end-user, includes pharmaceutical and biopharmaceutical companies, academic & research institutes and CROs & CDMOs. The CROs & CDMOs segment dominated the market in 2022. Comparing the cost of outsourcing PDX model-related research to CROs and CDMOs with the cost of building and sustaining in-house expertise. These businesses provide a variety of services that can be customized to fulfill certain research needs, ranging from model creation to drug testing.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Patient Derived Xenograft Model Market dominated this market in 2022 (45.80%). A large pharmaceutical sector, primarily based in the United States, is also present in North America. The need for PDX models is mostly driven by this sector of the economy. Pharmaceutical firms in North America depend on PDX models for their outstanding capacity to faithfully imitate human tumor responses due to their ongoing demand for novel treatment options.
This encourages research partnerships and cooperation with academic institutions, which in turn expands the market for PDX models. Further, the U.S. Patient derived xenograft model market held the largest market share, and the Canada Patient derived xenograft model market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: PATIENT DERIVED XENOGRAFT MODEL MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Europe Patient derived xenograft model market accounts for the second-largest market share. Multinational collaboration is the primary driver of PDX model expansion in Europe. European nations support cross-institutional cooperation, which promotes substantial information transfer and resource sharing for PDX model research. This culture of cooperation generates a vibrant research ecosystem where knowledge and information are openly exchanged, speeding the development of PDX model technology and applications. Further, the German Patient derived xenograft model market held the largest market share, and the UK Patient derived xenograft model market was the fastest growing market in the European region.
The Asia-Pacific Patient Derived Xenograft Model Market is expected to grow at the fastest CAGR from 2023 to 2032. The booming biotechnology industry in the Asia-Pacific region is primarily responsible for the area's rise in the PDX model market. Significant investments have been made in medication development and life sciences research by nations including China, Japan, and South Korea. With the development of biotechnology, PDX models have become crucial resources for preclinical drug testing and cancer research.
Moreover, China’s Patient derived xenograft model market held the largest market share, and the Indian Patient derived xenograft model market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Patient derived xenograft model market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Patient derived xenograft model industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Patient derived xenograft model industry to benefit clients and increase the market sector. In recent years, the Patient derived xenograft model industry has offered some of the most significant advantages to medicine. Major players in the Patient derived xenograft model market, including Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. and others, are attempting to increase market demand by investing in research and development operations.
Charles River Laboratories International Inc. (Charles River), a contract research organization (CRO), provides essential products and services to speed up analysis, medication discovery, and development. It offers a variety of services for fundamental research, drug discovery, and safety assessment. The company also offers assistance with production, operations, and employment. It provides treatments for conditions affecting the cardiovascular, nervous, metabolic, inflammatory, pulmonary, musculoskeletal, and oncological systems. Charles River provides services to prestigious hospitals, universities, government agencies, pharmaceutical and biotechnology companies, and other clientele. The headquarters of Charles River are located in Wilmington, Massachusetts, a city in the US.
WuXi AppTec Co Ltd (Wuxi AppTec) is a pharmaceutical and medical equipment outsourcing company. It provides clinical research, oligonucleotides and peptides, cell therapy, gene therapy, small molecule drugs, as well as clinical and regulatory services. WuXi AppTec also offers services for small molecule pharmaceutical research and development, advanced medicines, medical devices, lab testing, bioanalytical, chemical, and toxicological analysis, as well as fully integrated testing and testing services. The company has facilities for production and research in South Korea, the US, and China. Wuxi AppTec is headquartered in Shanghai, China.
| Report Attribute/Metric | Details |
| Market Size 2024 | 0.32 (USD Billion) |
| Market Size 2025 | 0.36 (USD Billion) |
| Market Size 2034 | 1.10 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 13.30 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Tumor Type, Model Type, End-user, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. |
| Key Market Opportunities | Reduced Animal Testing. |
| Key Market Dynamics | Rising Cancer Incidence. |
Patient Derived Xenograft Model Market Highlights:
Frequently Asked Questions (FAQ):
The Patient derived xenograft model market size was valued at USD 0.247 Billion in 2022.
The market is projected to grow at a CAGR of 13.30% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp.
The Breast Cancer category dominated the market in 2022.
The Mice had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
